Style Editor Docs
     
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • US FDA IDE Pre-Submission
      • US FDA IDE Updates
    • Human Clinical Trials
  • IsoPet®
    • Regional Clinics
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • IsoPet® Therapy Pets
    • Veterinarians
    • Animal Studies
      • Canine Studies
      • Feline Studies
    • Our IsoPet® Mission
  • About Us
    • Management & Consultants
    • Advisory Boards
    • Contact - RadioGel™ | IsoPet®
  • Blog
  • Investors
    • Press Releases
    • Board of Directors
    • SEC Filings
    • Contact - Investor Relations
   Contact Us
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • US FDA IDE Pre-Submission
      • US FDA IDE Updates
    • Human Clinical Trials
  • IsoPet®
    • Regional Clinics
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • IsoPet® Therapy Pets
    • Veterinarians
    • Animal Studies
      • Canine Studies
      • Feline Studies
    • Our IsoPet® Mission
  • About Us
    • Management & Consultants
    • Advisory Boards
    • Contact - RadioGel™ | IsoPet®
  • Blog
  • Investors
    • Press Releases
    • Board of Directors
    • SEC Filings
    • Contact - Investor Relations
    December 01, 2022

    Vivos November Update

    These are the monthly highlights of our progress. 

     

    American Association of Equine Practitioners Conference

     

    We had a booth at the 68th Annual Convention of the American Association of Equine Practitioners, AAEP, in San Antonio, Texas. This is the largest equine conference of the year, with 4200 people registered (1400 exhibitors, 2800 DVMs, Guests, Students, and Techs). This and our recent ad in The Horse magazine were excellent vehicles to introduce the equine community to IsoPet® therapy. We obtained new contacts considering becoming an equine therapy IsoPet® regional center. This will require significant follow-up effort.

     

    John Heindrcih, PhD, DVM attended and provided important insights. He recently retired as the owner of the Ventana Animal Hospital in Albuquerque, NM, and is our new veterinarian consultant.

     

    Johns Hopkins VX-2/Rabbit Study

      

    We translated our animal test plan into the FDA GLP protocol. It is now divided into Phase 1 to determine biokinetics and Phase 2 to measure effectiveness. Johns Hopkins obtained the IACUC approval to initiate Phase 1 and is preparing an amendment to include the control group of rabbits for Phase 2.

     

    "This and our recent ad in The Horse magazine were excellent vehicles to introduce the equine community to IsoPet® therapy. We obtained new contacts considering becoming an equine therapy IsoPet® regional center."

    (Mike Korenko, Sc.D • CEO • President – December 1, 2022)

     Quality Management System

     

    We are continually strengthening our Quality Management System. This month we audited IsoTherapeutics, our current IsoPet® particle manufacturing center. We also completed the sterilization validation runs on our particles, which is necessary for the FDA IDE.

     

    Intellectual Property

     

    Protecting our intellectual property is always a priority. We are working on two new patents, but I can only publicly disclose the content after they are filed.

     

    Mike Korenko, Sc. D

    CEO & President Vivos, Inc.

     

    CONTACT:
    Vivos Inc.
    Michael K. Korenko, Sc.D.
    President & CEO

     

    tagPlaceholderTags:

    Write a comment

    Comments: 1
    • #1

      Warren Wicher (Wednesday, 14 December 2022 19:46)

      I came across a perplexing story about Duke University developing a “gel therapy” using Iodine 131.
      It was disturbing as it seemed to intrude on Radiogel/Isopet technology,
      https://scitechdaily.com/most-effective-treatment-yet-new-radioactive-tumor-implant-obliterates-pancreatic-cancer/
      Should there be concern about “David vs. Goliath regarding Big Pharma displacing micro cap companies?
      Just a concerned advocate.

    Vivos, Inc.

    Precision Radionuclide Therapy (PRnT)

    OTCQB: RDGL

    contact: info@radiogel.com


    Home Page Cover Image: 

     

    Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.

     

    Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.

    RadioGel™ is a hydrogel liquid containing tiny yttrium-90 (90Y)  phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

    IsoPet® Therapy Application(s)


    Precision Radionuclide Therapy (PRnT)


    Vivos Inc.
     - (OTCQB: RDGL) Investor Relations 

    Contact

     

    Main colors
       bg-primary
       bg-primary-light
       bg-primary-dark
       bg-secondary
       bg-secondary-dark
    Template sections
       body
       top-header
       header
       content
    Footer Styles
       background
       text color
       link color
       horizontal line
    Buttons
       style 1
       style 2
       style 3
    Other elements
      social icons
      navigation color
      subnav background
    Mobile navigation
       background color
       navigation color
    Template configurations
    has-right-nav g-font
    navigation styles
    size-15 weight-400 snip-nav
    content styles
    form-white
    footer styles
    o-form color-white
    Typography
    Heading H1
    weight-600
    Heading H2
    weight-600
    Heading H3
    weight-600
    Buttons
    weight-600 is-uppercase
    Animations

    Note:
    All changes made here will be applied to your entire website.
    is-switcher admin-only

    RadioGel™ Logo

    Precision Radionuclide Therapy (PRnT)

    draggable-logo

    About | Privacy Policy | Cookie Policy | Sitemap
    © 2022 Vivos Inc. | RadioGel™ is a registered trademark | IsoPet® is a registered trademark
    Log out | Edit
    • Scroll to top